Biothera Pharmaceuticals Presents Translational Data from Ongoing Clinical Trials Showing Imprime PGG in Combination with Merck’s KEYTRUDA® (pembrolizumab) Drives Innate and Adaptive Immune Responses in Tumors
April 16, 2018 09:00 ET
|
Biothera Pharmaceuticals, Inc.
EAGAN, Minn., April 16, 2018 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. today announced the presentation of new translational data from ongoing phase 2 clinical trials combining Biothera’s...
Biothera Pharmaceuticals Commences Phase 2 Head and Neck Cancer Study Evaluating Combination of Imprime PGG and Merck’s KEYTRUDA® (pembrolizumab)
February 06, 2018 09:30 ET
|
Biothera Pharmaceuticals, Inc.
EAGAN, Minn., Feb. 06, 2018 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. announced today that patient treatment has commenced in its Phase 2 clinical study in squamous cell carcinoma of the...
Biothera Pharmaceuticals Enters Cancer Immunotherapy Clinical Trial Collaboration Agreement
November 28, 2017 09:00 ET
|
Biothera Pharmaceuticals, Inc.
EAGAN, Minn., Nov. 28, 2017 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. today announced that it has entered into a clinical trial collaboration agreement with Genentech, Inc., a member of the...
Biothera Pharmaceuticals to Present at the 29th Annual Piper Jaffray Healthcare Conference
November 21, 2017 09:23 ET
|
Biothera Pharmaceuticals, Inc.
EAGAN, Minn., Nov. 21, 2017 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. today announced that Chief Executive Officer Barry Labinger will present at the 29th Annual Piper Jaffray Healthcare...
Biothera Pharmaceuticals Presents Data Broadening Imprime PGG Mechanism of Action
November 13, 2017 09:30 ET
|
Biothera Pharmaceuticals, Inc.
Reduces expression of IDO, a potent suppressor of an anti-cancer T cell response Supplementation with IVIG boosts biomarker levels, restoring Imprime-driven pharmacodynamic responses EAGAN, Minn.,...
Biothera Pharmaceuticals Presents Preclinical Data Showing Imprime PGG Activates Natural Killer Cell-Mediated Tumor Killing
October 30, 2017 09:00 ET
|
Biothera Pharmaceuticals, Inc.
EAGAN, Minn., Oct. 30, 2017 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. announced today the presentation of new preclinical findings showing that the Company’s Phase 2 cancer immunotherapy...
Biothera Pharmaceuticals Announces Presentations on Imprime PGG at Three Upcoming Healthcare Conferences
September 28, 2017 12:09 ET
|
Biothera Pharmaceuticals, Inc.
EAGAN, Minn., Sept. 28, 2017 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. today announced that it will present new research at three upcoming healthcare conferences for Imprime PGG, Biothera’s...
Biothera Pharmaceuticals Announces Initiation of Phase 1b/2 Clinical Study Evaluating Combination of Imprime PGG and Merck’s KEYTRUDA in Non-Small Cell Lung Cancer
July 19, 2017 10:00 ET
|
Biothera Pharmaceuticals, Inc.
EAGAN, Minn., July 19, 2017 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. today announced that the Big Ten Cancer Research Consortium has begun patient dosing in a Phase 1b/2 clinical study to...
Biothera Pharmaceuticals Announces Presentation at the Upcoming 2017 American Society of Clinical Oncology (ASCO) Annual Meeting
May 31, 2017 09:00 ET
|
Biothera Pharmaceuticals, Inc.
EAGAN, Minn., May 31, 2017 (GLOBE NEWSWIRE) -- Biothera Pharmaceuticals, Inc. announced today that a poster about the design of IMPRIME-1™, the company’s ongoing Phase 2 clinical trial in advanced...